Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedNew revision entry v3.5.0 added to the history. The v3.4.3 entry was removed.SummaryDifference0.0%

- Check24 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check31 days agoChange DetectedThe trial status is updated to Terminated with primary results showing no benefit from canakinumab. The previous Active, not recruiting status has been removed.SummaryDifference0.2%

- Check52 days agoChange DetectedThe latest version adds a Contacts/Locations section and a Study Status update to the record. These additions improve access to study contact information and the current recruitment status.SummaryDifference0.5%

- Check59 days agoChange DetectedAdded a site-wide funding/operating status notice and Revision: v3.4.1; removed Revision: v3.4.0.SummaryDifference0.3%

- Check66 days agoChange DetectedUI improvements include a glossary toggle and color-coded highlights (green for additions, red for deletions, and highlighting of changes) in the study record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.